Literature DB >> 16472052

Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated patients with type 1 diabetes.

M Orsini-Federici1, J Akwe Akwi, V Canonico, R Celleno, P Ferolla, R Pippi, C Tassi, A Timi, M Massi Benedetti.   

Abstract

BACKGROUND: This study was performed to define the clinical relevance of early changes of capillary 3beta-hydroxybutyrate (3betaOHB), for detection of metabolic deterioration before occurrence of overt diabetic ketoacidosis following interruption of continuous subcutaneous insulin infusion (CSII).
METHODS: An open clinical trial was performed with eight patients with type 1 diabetes on CSII therapy. After an overnight fast, at 8 a.m. (T0) CSII was interrupted for 4 h. At noon (T240) CSII was re-established, and at 4 p.m. (T480) the study was ended. Blood glucose (BG) and capillary and plasma 3betaOHB were measured at 30-min intervals, plasma insulin at 60-min intervals, and urinary ketones at 120-min intervals.
RESULTS: After CSII interruption mean BG increased from 149.8+/-54.4 mg/dL at T0 to 224.8+/-56.2 mg/dL at T240 (P<0.05), and mean capillary 3betaOHB increased from 0.1+/-0.1 mmol/L at T0 to 0.9+/-0.6 mmol/L at T240 (P<0.001). The rate of increase of capillary 3betaOHB was faster and significantly more relevant than that of BG (P<0.05). The restoration of CSII produced a significant reduction of mean BG and capillary 3betaOHB (T480, 119.5+/-24 mg/dL and 0.2+/-0.2 mmol/L, respectively; P<0.05 for both vs. T240). The recovery of capillary 3betaOHB was significantly faster than that of BG (P=0.03).
CONCLUSIONS: The dynamic evaluation of changes of capillary 3betaOHB levels can represent a useful support to home BG monitoring in the event of CSII interruption, providing faster information on early metabolic deterioration due to insulin deprivation and allowing preventative action for avoiding the evolution towards overt diabetic ketoacidosis. After reintroduction of insulin infusion the monitoring of the faster recovery of 3betaOHB relative to BG can provide useful information for the prevention of late hypoglycemia due to insulin overinfusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472052     DOI: 10.1089/dia.2006.8.67

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  10 in total

1.  Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

Authors:  David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

2.  Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension.

Authors:  R Paul Wadwa; H Peter Chase; Dan Raghinaru; Bruce A Buckingham; Irene Hramiak; David M Maahs; Laurel Messer; Trang Ly; Tandy Aye; Paula Clinton; Craig Kollman; Roy W Beck; John Lum
Journal:  Pediatr Diabetes       Date:  2016-07-12       Impact factor: 4.866

Review 3.  Outpatient Management of Pediatric Type 1 Diabetes.

Authors:  Joni K Beck; Fran R Cogen
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Sep-Oct

4.  Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia.

Authors:  Bruce A Buckingham; Fraser Cameron; Peter Calhoun; David M Maahs; Darrell M Wilson; H Peter Chase; B Wayne Bequette; John Lum; Judy Sibayan; Roy W Beck; Craig Kollman
Journal:  Diabetes Technol Ther       Date:  2013-07-24       Impact factor: 6.118

5.  Real-Time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas.

Authors:  Eyal Dassau; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Howard Zisser; Lois Jovanovic; H Peter Chase; Darrell M Wilson; Bruce A Buckingham; Francis J Doyle
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 17.152

6.  Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.

Authors:  Bruce Buckingham; H Peter Chase; Eyal Dassau; Erin Cobry; Paula Clinton; Victoria Gage; Kimberly Caswell; John Wilkinson; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Francis J Doyle
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

7.  Continuous Ketone Monitoring Consensus Report 2021.

Authors:  Kevin T Nguyen; Nicole Y Xu; Jennifer Y Zhang; Trisha Shang; Ananda Basu; Richard M Bergenstal; Kristin Castorino; Kong Y Chen; David Kerr; Suneil K Koliwad; Lori M Laffel; Nestoras Mathioudakis; L Kurt Midyett; Joshua D Miller; James H Nichols; Francisco J Pasquel; Priya Prahalad; Mark R Prausnitz; Jane Jeffrie Seley; Jennifer L Sherr; Elias K Spanakis; Guillermo E Umpierrez; Amisha Wallia; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2021-10-04

8.  Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.

Authors:  Roy W Beck; Dan Raghinaru; R Paul Wadwa; H Peter Chase; David M Maahs; Bruce A Buckingham
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

Review 9.  Potential Clinical Applications for Continuous Ketone Monitoring in the Hospitalized Patient with Diabetes.

Authors:  Michelle Jaromy; Joshua D Miller
Journal:  Curr Diab Rep       Date:  2022-08-19       Impact factor: 5.430

10.  A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.

Authors:  David M Maahs; Peter Calhoun; Bruce A Buckingham; H Peter Chase; Irene Hramiak; John Lum; Fraser Cameron; B Wayne Bequette; Tandy Aye; Terri Paul; Robert Slover; R Paul Wadwa; Darrell M Wilson; Craig Kollman; Roy W Beck
Journal:  Diabetes Care       Date:  2014-05-07       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.